Active, not recruitingPhase 2NCT05966480
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alumis Inc
- Intervention
- Envudeucitinib(drug)
- Enrollment
- 408 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Investigator Site #1046, Anniston, Alabama, United States
- Investigator Site #1104, La Jolla, California, United States
- Investigator Site #1050, Los Alamitos, California, United States
- Investigator Site #1168, Mission Hills, California, United States
- Investigator Site #1174, Napa, California, United States
- Investigator Site #1061, Upland, California, United States
- Investigator Site #1048, Aventura, Florida, United States
- Investigator Site #1063, Avon Park, Florida, United States
- Investigator Site #1176, Bradenton, Florida, United States
- Investigator Site #1045, Clearwater, Florida, United States
- Investigator Site #1055, Coral Gables, Florida, United States
- Investigator Site #1097, Coral Springs, Florida, United States
- Investigator Site #1091, Daytona Beach, Florida, United States
- Investigator Site #1051, DeBary, Florida, United States
- Investigator Site #1087, Hollywood, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05966480 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07339332A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT07109986UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus NephritisNanjing IASO Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGNANCT07196072A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic PainUniversity of Michigan
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGNCT06659029Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersAstraZeneca
- RECRUITINGPHASE1NCT06613360A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusCullinan Therapeutics Inc.
- RECRUITINGNCT07017868Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis PatientsSohag University